

# Evaluating risk of dementia in older people: a pathway to personalized prevention?

Andrew Sommerlad <sup>1,2\*</sup> and Naaheed Mukadam <sup>1,2</sup>

<sup>1</sup>Division of Psychiatry, University College London, London, UK; and <sup>2</sup>Camden and Islington NHS Foundation Trust, London, UK

Online publish-ahead-of-print 6 October 2020

**This editorial refers to ‘Impact of cardiovascular risk factors and genetics on 10-year absolute risk of dementia: risk charts for targeted prevention’<sup>†</sup>, by R. Rasmussen et al., on page 4024.**

Over 40 million people worldwide have dementia,<sup>1</sup> with an estimated global cost of US\$1 trillion annually.<sup>2</sup> The number of people with dementia is expected to double every 20 years due to rapid global demographic changes, making dementia one of the largest socioeconomic and health challenges worldwide. Age-standardized rates of dementia are reported to have decreased in several high-income countries over the past 20 years,<sup>3</sup> probably related to successive generations’ higher levels of education, and earlier detection and treatment of illness risk factors.<sup>4</sup> This suggests that dementia can be prevented by modifications to dementia risk factors, with recent evidence showing that feasible interventions targeting some of these risk factors could result in savings of £1.9 billion per year in England.<sup>5</sup> That ‘prevention is better than care’ is even clearer in the light of repeated failures of novel drug approaches to treating established dementia.<sup>6</sup> However, while we have strong evidence for a causal relationship for many risk factors for dementia,<sup>7</sup> there is still very limited evidence that we can actually prevent it, so future approaches are likely to require personalized prevention, meaning that it will need to be targeted towards the right risk factors in the right people.

In this issue of the *European Heart Journal*, Rasmussen and colleagues aim to develop risk score tools to identify people at high risk of developing dementia according to established genetic and lifestyle factors.<sup>8</sup> Two large Danish cohorts were combined to generate a sample of >60 000 people who were followed for up to 25 years, and a combination of traditional statistical approaches and machine learning was used to identify the strongest predictors of dementia risk from a shortlist of candidates: age, sex, education, diabetes, hypertension, smoking status, and genetic risk according to both apolipoprotein E (APOE) genotype and a polygenic score (Figure 1).

These were then incorporated in predictive statistical models which accounted for the competing possibility of dying before dementia development<sup>9</sup> to give the probability of developing dementia during 10 years according to risk factor status. The authors then created a series of colour-coded charts indicating that, for example, a non-smoking man aged 50–59 years with high educational attainment, no diabetes, and favourable genetic profile has a <1% chance of developing dementia during the subsequent 10 years, whereas a female smoker aged over 80, with limited education, diabetes, two APOE ε4 alleles, and a high number of risk genes has a 66% chance of developing dementia over the next decade.


Several previous risk scores have been developed for dementia either to guide prevention<sup>10</sup> or to support identification of people for more detailed assessment,<sup>11</sup> but this study’s approach has methodological strengths and includes a more comprehensive range of risk factors. The generation for the first time of dementia risk charts, akin to those used for cardiovascular risk from the Framingham study,<sup>12</sup> is a potentially important step forward as it facilitates the identification of high-risk individuals based on a range of risk factors, which could help to target prevention towards those who need it most. This is particularly important as some recent multicomponent trials aimed at preventing dementia found that the most benefit was in those who had the highest baseline risk,<sup>13</sup> so more targeted prevention could yield greater impact. Focusing on potentially modifiable risk factors for dementia could also promote a positive public health message related to the potential modification of dementia risk by changing risk factors. The pessimism felt by those who assume that dementia is an inevitable consequence of ageing, or that a positive family history of dementia indicates that they will follow the same disease course, is misplaced according to this study and previous research<sup>14</sup> which have shown the likely modifiability of dementia risk with positive lifestyle approaches, even in the face of unmodifiable age, genotype, and sex. Perhaps stopping smoking and effective diabetes management in the woman described above may reduce her risk from 66% to 55%?

The opinions expressed in this article are not necessarily those of the Editors of the *European Heart Journal* or of the European Society of Cardiology.

<sup>†</sup> doi:10.1093/eurheartj/ehaa695.

\* Corresponding author. Division of Psychiatry, University College London, 6th Floor, Maple House, 149 Tottenham Court Rd, London W1T 7NF, UK. Tel: +44 20 7679 9248, Email: [a.sommerlad@ucl.ac.uk](mailto:a.sommerlad@ucl.ac.uk)

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2020. For permissions, please email: [journals.permissions@oup.com](mailto:journals.permissions@oup.com).



**Figure 1** Risk factors for dementia. Several established risk factors contribute to dementia risk: these can be divided into those which are unmodifiable, which are age, sex, and genetic risk, and potentially modifiable risk factors, which include low level of education, physical inactivity, high alcohol intake, smoking, hypertension, and diabetes. These interact throughout the life course to increase dementia risk by amyloid and tau-mediated neuro-pathology, cerebrovascular and inflammatory mechanisms, and reduced cognitive reserve. The linked article by Rasmussen et al.<sup>8</sup> has generated a colour-coded risk calculator where green indicates low risk and red shows high risk of developing dementia during the subsequent 10 years.

The evidence for dementia being truly preventable is, however, scarce. Only one randomized controlled trial (RCT) has successfully reduced risk from dementia, with effective management of hypertension,<sup>15</sup> and several other studies have not resulted in dementia reduction. It may be that the insidious onset of dementia from neuropathological damage accumulated over many decades means that RCTs of dementia prevention conducted in late life are too late to find efficacy and that preventative approaches are likely to be most effective during midlife. Additionally, those at higher risk from dementia may benefit more from preventative trials even if treating their risk factors does not, in itself, prevent dementia.

Models such as that developed by Rasmussen and colleagues must be able to evolve over time for several reasons: understanding of risk factors continues to develop; genetic and biomarker availability is changing; and validation in diverse populations is important particularly as genetic markers are likely to differ in those with different ancestry. Dementia's long prodromal period means that associations reported with an insufficient interval between ascertainment of risk factor and dementia status may be due to reverse causation bias. The example of the association of body mass index (BMI) with dementia is illustrative, as low BMI appears to be associated with dementia

when follow-up to dementia diagnosis is <5 years, but high BMI is associated with dementia when follow-up is >10 years;<sup>16</sup> low weight therefore is a consequence rather than cause of dementia and in fact obesity is a risk factor which should be addressed in midlife. The associations included in this risk score are uncontroversial, but inclusion of other emerging modifiable risk factors may improve predictive accuracy.

Risk models may also need to develop according to changes in the availability of data. The risk score developed by Rasmussen and colleagues assumes that genetic data will be available for individuals. While the excess risk due to APOE status and genome-wide association study (GWAS) scores are clearly important, use of genetic testing is variable in clinical diagnostic practice for dementia and rare for non-clinical groups; genetic data availability is likely to increase in future, but remains controversial. In addition, several cerebrospinal fluid and imaging biomarkers for dementia risk currently show reasonable predictive value, and work continues to develop accurate markers which are more feasible to collect on a large scale, such as in plasma, so incorporating these markers in risk score models may be instructive. Furthermore, the accuracy of cardiovascular risk score models has been criticized for lacking validity in different

populations,<sup>17</sup> so validating these models in diverse ethnic and social settings is likely to be required, especially in view of global variations in risk factor profiles for dementia.<sup>18</sup> Risk scores need to balance simplicity of use with accuracy, however, and evolution of previous scores has been criticized for creating confusion.<sup>19</sup>

Improving public understanding of dementia is a key component of prevention. In a US study, just over half of adults aged 50–64 reported it 'unlikely' that they would develop dementia and only 5% had discussed dementia prevention strategies with a doctor, while many were using non-evidence-based approaches such as nutritional supplementation.<sup>20</sup> An international survey of 70 000 people from 155 countries found that a quarter thought that there is nothing that can be done to prevent dementia.<sup>21</sup> The message from The Lancet Commission on Dementia that steps towards dementia prevention can be taken at any point during the life course<sup>7</sup> suggests that action is required from individuals and organizations. In the UK, the National Health Service offers a 'Health check' to all adults aged between 40 and 74 to look for early signs of illness, and dementia prevention advice is built into this. Quantifying dementia risk using a score such as that developed by Rasmussen and colleagues may be a valuable addition if it allowed the clinician to accurately model the effect of lifestyle modifications and to triage high-risk individuals towards more intensive preventative measures. The economic, social, and individual costs of dementia mean that its prevention should be a priority for all those at risk as well as policymakers and clinicians.

## Acknowledgements

A.S. is supported by a grant from the Wellcome Trust (200163/Z/15/Z). N.M. is supported by a grant from the Alzheimer's Society (479(AS-SF-18b-001)). A.S. and N.M. are supported by the University College London Hospitals' National Institute for Health Research Biomedical Research Centre.

**Conflict of interest:** none declared.

## References

1. GBD 2016 Dementia Collaborators. Global, regional, and national burden of Alzheimer's disease and other dementias, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet Neurol* 2019;**18**:88–106.
2. Patterson C. *World Alzheimer Report 2018: The State of the Art of Dementia Research: New Frontiers*. London: Alzheimer's Disease International (ADI); 2018. p32–36.
3. Wu Y-T, Beiser AS, Breteler MM, Fratiglioni L, Helmer C, Hendrie HC, Honda H, Ikram MA, Langa KM, Lobo A, Matthews FE, Ohara T, Pérès K, Qiu C, Seshadri S, Sjölund BM, Skoog I, Brayne C. The changing prevalence and incidence of dementia over time—current evidence. *Nat Rev Neurol* 2017;**13**:327–339.
4. Langa KM, Larson EB, Crimmins EM, Faul JD, Levine DA, Kabeto MU, Weir DR. A comparison of the prevalence of dementia in the United States in 2000 and 2012. *JAMA Intern Med* 2017;**177**:51–58.
5. Mukadam N, Anderson R, Knapp M, Wittenberg R, Karagiannidou M, Costafreda SG, Tutton M, Alessi C, Livingston G. Effective interventions for potentially modifiable late-onset dementia risk factors: their costs and cost-effectiveness. *Lancet Healthy Longevity* 2020 (in press).
6. Cummings J, Lee G, Ritter A, Sabbagh M, Zhong K. Alzheimer's disease drug development pipeline: 2019. *Alzheimers Dement* 2019;**5**:272–293.
7. Livingston G, Huntley J, Sommerlad A, Ames D, Ballard C, Banerjee S, Brayne C, Burns A, Cohen-Mansfield J, Cooper C, Costafreda SG, Dias A, Fox N, Gitlin LN, Howard R, Kales HC, Kivimäki M, Larson EB, Ogunniyi A, Orgeta V, Ritchie K, Rockwood K, Sampson EL, Samus Q, Schneider LS, Selbæk G, Teri L, Mukadam N. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. *Lancet* 2020;**396**:413–446.
8. Rasumussen I, Rasmussen K, Nordestgaard B, Tybjaerg-Hansen A, Frikke-Schmidt R. Impact of cardiovascular risk factors and genetics on 10-year absolute risk of dementia: risk charts for targeted prevention. *Eur Heart J* 2020;41:4024–4033.
9. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. *J Am Stat Assoc* 1999;**94**:496–509.
10. Li J, Ogrodnik M, Devine S, Auerbach S, Wolf PA, Au R. Practical risk score for 5-, 10-, and 20-year prediction of dementia in elderly persons: Framingham Heart Study. *Alzheimers Dement* 2018;**14**:35–42.
11. Walters K, Haroon S, Petersen I, Iliffe S, Omar R, Nazareth I, Rait G. Predicting dementia risk in primary care: development and validation of the Dementia Risk Score using routinely collected data. *BMC Med* 2016;**14**:6.
12. Anderson KM, Odell PM, Wilson PW, Kannel WB. Cardiovascular disease risk profiles. *Am Heart J* 1991;**121**:293–298.
13. Richard E, Moll Van Charante EP, Hoevenaer-Blom MP, Coley N, Barbera M, Van Der Groep A, Meiller Y, Mangialasche F, Beishuizen C B, Jongstra S, Van Middelaar T, Van Wanrooij L L, Ngandu T, Guilleumont J, Andrieu S, Brayne C, Kivipelto M, Soininen H, Van Gool WA. Healthy ageing through internet counselling in the elderly (HATICE): a multinational, randomised controlled trial. *The Lancet Digital Health* 2019;**1**:e424–e434.
14. Lourida I, Hannon E, Littlejohns TJ, Langa KM, Hyppönen E, Kuźma E, Llewellyn DJ. Association of lifestyle and genetic risk with incidence of dementia. *JAMA* 2019;**322**:430–437.
15. Peters R, Beckett N, Forette F, Tuomilehto J, Clarke R, Ritchie C, Waldman A, Walton I, Poulter R, Ma S, Coma M, Burch L, Fletcher A, Bulpitt C; HYVET investigators. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. *Lancet Neurol* 2008;**7**:683–689.
16. Kivimäki M, Luukkonen R, Batty GD, Ferrie JE, Pentti J, Nyberg ST, Shipley MJ, Alfredsson L, Fransson EI, Goldberg M, Knutsson A, Koskenvuo M, Kuosma E, Nordin M, Suominen SB, Theorell T, Vuoksimaa E, Westerholm P, Westerlund H, Zins M, Kivipelto M, Vahtera J, Kaprio J, Singh-Manoux A, Jokela M. Body mass index and risk of dementia: analysis of individual-level data from 1.3 million individuals. *Alzheimers Dement* 2018;**14**:601–609.
17. Hense H-W, Schulte H, Löwel H, Assmann G, Keil UJ. Framingham risk function overestimates risk of coronary heart disease in men and women from Germany—results from the MONICA Augsburg and the PROCAM cohorts. *Eur Heart J* 2003;**24**:937–945.
18. Mukadam N, Sommerlad A, Huntley J, Livingston G. Population attributable fractions for risk factors for dementia in low-income and middle-income countries: an analysis using cross-sectional survey data. *Lancet Glob Health* 2019;**7**:e596–e603.
19. Liew SM, Blacklock C, Hislop J, Glasziou P, Mant D. Cardiovascular risk scores: qualitative study of how primary care practitioners understand and use them. *Br J Gen Pract* 2013;**63**:e401–e407.
20. Maust DT, Solway E, Langa KM, Kullgren JT, Kirch M, Singer DC, Malani P. Perception of dementia risk and preventive actions among US adults aged 50 to 64 years. *JAMA Neurol* 2020;**77**:259–262.
21. Alzheimer's Disease International. *World Alzheimer Report 2019: Attitudes to Dementia*. London: Alzheimer's Disease International; 2019.